(Q36628704)

15 August 2017

1 reference

title

Clinical aspects of epidermal growth factor receptor inhibitors: benefit and risk (English)

1 reference

15 August 2017

Tefurumi Kato

1

1 reference

PubMed ID

17052296

15 August 2017

Kazuto Nishio

series ordinal

2

1 reference

15 August 2017

1 November 2006

1 reference

15 August 2017

1 reference

15 August 2017

11

1 reference

15 August 2017

6

1 reference

15 August 2017

693-698

1 reference

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

15 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00940.X

Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00940.X

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00940.X

Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00940.X

ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00940.X

Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00940.X

Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00940.X

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00940.X

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00940.X

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00940.X

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00940.X

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00940.X

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00940.X

Erlotinib in previously treated non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00940.X

Severe acute interstitial pneumonia and gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00940.X

Acute lung injury as a possible adverse drug reaction related to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00940.X

Diffuse alveolar damage after ZD1839 therapy in a patient with non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00940.X

Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa, ZD1839) in chemotherapy-resistant non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00940.X

Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00940.X

Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00940.X

Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00940.X

First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00940.X

United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00940.X

Interstitial lung disease associated with drug therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00940.X

Imaging of gefitinib-related interstitial lung disease: multi-institutional analysis by the West Japan Thoracic Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00940.X

Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00940.X

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00940.X

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00940.X

Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00940.X

Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00940.X

Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00940.X

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00940.X

High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00940.X

Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00940.X

Erlotinib in lung cancer - molecular and clinical predictors of outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00940.X

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00940.X

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00940.X

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00940.X

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00940.X

10.1111/J.1440-1843.2006.00940.X

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference

PubMed ID

17052296